VCEL
Neutral signalScored 2026-08-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Vericel Corporation
- Nom
- Vericel Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 398
- PDG
- Dominick C. Colangelo
- Site web
- https://vcel.com
- Marché
- ABEOBVSIARTMDWDMDXGMESO
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 7 000 titres (~311 710,00 $ US)
- Insiders
- MCLAUGHLIN KEVIN F
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$804,560
Avg sell (VWAP, 90d window) $45.97 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$804,560 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-12 | MCLAUGHLIN KEVIN F | Sell · S · 10b5-1 | 7,000 | $44.53 | $311,710 | Form 4 |
| 2026-08-03 | Halpin Michael | Sell · S · 10b5-1 | 10,000 | $46.84 | $468,400 | Form 4 |
| 2026-07-30 | SIEGAL JONATHAN | Sell · S · 10b5-1 | 500 | $48.90 | $24,450 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-16 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
VCEL delivered a strong Q2 2026 earnings beat with 22% revenue growth, raised full-year guidance, and launched a share repurchase program, confirming durable momentum in MACI and Burn Care segments.
The first sentence of the analysis written for VCEL on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $805K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $805K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 5.03 · operating margin 4.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.4% | 72.6% | 68.6% | 66.8% | 67.9% | |
| Ebit Margin | 6.9% | 4.7% | -0.9% | -9.5% | -4.9% | |
| Ebitda Margin | 11.0% | 7.0% | 1.5% | -7.1% | -3.0% | |
| Operating Profit Margin | 4.0% | 1.9% | -3.3% | -10.4% | -5.0% | |
| Pretax Profit Margin | 6.3% | 4.4% | -1.2% | -9.7% | -4.9% | |
| Continuous Operations Profit Margin | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% | |
| Net Profit Margin | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% | |
| Bottom Line Profit Margin | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% | |
| Current Ratio | 5.034 | 4.231 | 4.495 | 4.988 | 6.083 | |
| Quick Ratio | 4.677 | 3.886 | 4.209 | 4.561 | 5.569 | |
| Solvency Ratio | 0.209 | 0.113 | 0.011 | -0.158 | -0.062 | |
| Cash Ratio | 2.037 | 1.482 | 1.510 | 1.363 | 2.623 | |
| Price To Earnings Ratio | 109.121 | 261.476 | -532.287 | -75.257 | -245.625 | |
| Price To Earnings Growth Ratio | 1.910 | -0.632 | 6.581 | -0.634 | 0.696 | |
| Forward Price To Earnings Growth Ratio | 1.910 | -0.632 | 6.581 | -0.634 | 0.696 | |
| Price To Earnings Diluted Ratio | 112.531 | 274.550 | -532.287 | -75.257 | -245.625 | |
| Price To Earnings Diluted Growth Ratio | 1.876 | -0.688 | 6.581 | -0.634 | 0.675 | |
| Price To Book Ratio | 5.137 | 9.187 | 7.500 | 6.457 | 10.714 | |
| Price To Sales Ratio | 6.594 | 11.307 | 8.580 | 7.553 | 11.694 | |
| Price To Free Cash Flow Ratio | 73.613 | -461.580 | 217.322 | 123.021 | 86.454 | |
| Price To Operating Cash Flow Ratio | 35.095 | 46.116 | 47.993 | 70.187 | 62.891 | |
| Debt To Assets Ratio | 0.201 | 0.228 | 0.249 | 0.174 | 0.206 | |
| Debt To Equity Ratio | 0.277 | 0.339 | 0.390 | 0.247 | 0.294 | |
| Debt To Capital Ratio | 0.217 | 0.253 | 0.280 | 0.198 | 0.227 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.376 | 1.482 | 1.565 | 1.420 | 1.430 | |
| Working Capital Turnover Ratio | 1.531 | 1.472 | 1.277 | 1.166 | 1.338 | |
| Operating Cash Flow Ratio | 1.056 | 1.157 | 0.772 | 0.472 | 1.115 | |
| Operating Cash Flow Sales Ratio | 0.188 | 0.245 | 0.179 | 0.108 | 0.186 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.477 | -0.100 | 0.221 | 0.571 | 0.727 | |
| Debt Service Coverage Ratio | 1.882 | 26.840 | 3.417 | -33.776 | -1,125.500 | |
| Interest Coverage Ratio | 7.098 | 7.360 | -10.773 | -46.607 | -1,963.500 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.685 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.528 | 0.588 | 0.401 | 0.372 | 0.579 | |
| Capital Expenditure Coverage Ratio | 1.911 | 0.909 | 1.283 | 2.328 | 3.669 | |
| Dividend Paid And Capex Coverage Ratio | 1.911 | 0.909 | 1.283 | 2.328 | 3.669 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 60.076 | 162.772 | 598.336 | -106.340 | -391.980 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.4% | ▲1.9% | ▲4.4% |
| Ebit Margin | 6.9% | ▲2.2% | ▲7.6% |
| Ebitda Margin | 11.0% | ▲4.0% | ▲9.1% |
| Operating Profit Margin | 4.0% | ▲2.1% | ▲6.6% |
| Pretax Profit Margin | 6.3% | ▲1.9% | ▲7.3% |
| Continuous Operations Profit Margin | 6.0% | ▲1.6% | ▲7.2% |
| Net Profit Margin | 6.0% | ▲1.6% | ▲7.2% |
| Bottom Line Profit Margin | 6.0% | ▲1.6% | ▲7.2% |
| Current Ratio | 5.034 | ▲0.803 | ▲0.068 |
| Quick Ratio | 4.677 | ▲0.791 | ▲0.097 |
| Solvency Ratio | 0.209 | ▲0.096 | ▲0.186 |
| Cash Ratio | 2.037 | ▲0.555 | ▲0.234 |
| Price To Earnings Ratio | 109.121 | ▼-152.355 | ▲205.636 |
| Price To Earnings Growth Ratio | 1.910 | ▲2.541 | ▲0.325 |
| Forward Price To Earnings Growth Ratio | 1.910 | ▲2.541 | ▲0.325 |
| Price To Earnings Diluted Ratio | 112.531 | ▼-162.019 | ▲205.749 |
| Price To Earnings Diluted Growth Ratio | 1.875 | ▲2.564 | ▲0.314 |
| Price To Book Ratio | 5.137 | ▼-4.050 | ▼-2.662 |
| Price To Sales Ratio | 6.595 | ▼-4.712 | ▼-2.551 |
| Price To Free Cash Flow Ratio | 73.613 | ▲535.194 | ▲65.847 |
| Price To Operating Cash Flow Ratio | 35.095 | ▼-11.021 | ▼-17.361 |
| Debt To Assets Ratio | 0.201 | ▼-0.027 | ▼-0.010 |
| Debt To Equity Ratio | 0.277 | ▼-0.061 | ▼-0.032 |
| Debt To Capital Ratio | 0.217 | ▼-0.036 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.376 | ▼-0.106 | ▼-0.079 |
| Working Capital Turnover Ratio | 1.532 | ▲0.060 | ▲0.174 |
| Operating Cash Flow Ratio | 1.056 | ▼-0.101 | ▲0.142 |
| Operating Cash Flow Sales Ratio | 0.188 | ▼-0.057 | ▲0.007 |
| Free Cash Flow Operating Cash Flow Ratio | 0.477 | ▲0.577 | ▲0.098 |
| Debt Service Coverage Ratio | 1.882 | ▼-24.959 | ▲227.309 |
| Interest Coverage Ratio | 7.098 | ▼-0.262 | ▲408.382 |
| Short Term Operating Cash Flow Coverage Ratio | 3.686 | ▲3.686 | ▲2.948 |
| Operating Cash Flow Coverage Ratio | 0.528 | ▼-0.060 | ▲0.035 |
| Capital Expenditure Coverage Ratio | 1.911 | ▲1.002 | ▼-0.109 |
| Dividend Paid And Capex Coverage Ratio | 1.911 | ▲1.002 | ▼-0.109 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 60.076 | ▼-102.696 | ▼-4.497 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.82B | $2.68B | $1.69B | $1.24B | $1.83B | |
| Enterprise value | $1.82B | $2.71B | $1.71B | $1.24B | $1.81B | |
| EV / Sales | 6.59x | 11.41x | 8.68x | 7.53x | 11.58x | |
| EV / Op. cash flow | 35.06x | 46.53x | 48.53x | 69.99x | 62.27x | |
| EV / Free cash flow | 73.54x | -465.77x | 219.75x | 122.67x | 85.59x | |
| EV / EBITDA | 60.08x | 162.77x | 598.34x | -106.34x | -391.98x | |
| Net debt / EBITDA | -0.06x | 1.46x | 6.62x | 0.30x | 3.93x | |
| Current ratio | 5.03x | 4.23x | 4.50x | 4.99x | 6.08x | |
| Income quality | 3.14x | 5.61x | -11.10x | -1.06x | -3.89x | |
| Graham number | $7 | $5 | — | — | — | |
| Graham net-net | $2 | $1 | $1 | $2 | $1 | |
| Tax burden | 95.1% | 98.6% | 134.4% | 104.5% | 98.5% | |
| Interest burden | 91.8% | 94.5% | 133.9% | 102.3% | 100.1% | |
| Working capital | $198.3M | $162.5M | $159.9M | $149.4M | $132.4M | |
| Invested capital | $377.1M | $342.0M | $281.9M | $214.3M | $191.4M | |
| Return on assets | 3.4% | 2.4% | -0.9% | -6.1% | -3.1% | |
| Operating ROA | 2.4% | 1.1% | -2.1% | -6.6% | -3.5% | |
| Return on tangible assets | 3.4% | 2.4% | -0.9% | -6.3% | -3.1% | |
| Return on equity | 4.7% | 3.5% | -1.4% | -8.7% | -4.4% | |
| Return on invested capital | 2.3% | 1.1% | -2.1% | -7.1% | -3.5% | |
| Return on capital employed | 2.5% | 1.2% | -2.1% | -7.2% | -3.6% | |
| Earnings yield | 0.9% | 0.4% | -0.2% | -1.3% | -0.4% | |
| Free cash flow yield | 1.4% | -0.2% | 0.5% | 0.8% | 1.2% | |
| Capex / Op. cash flow | 52.3% | 110.0% | 77.9% | 42.9% | 27.3% | |
| Capex / Depreciation | 239.1% | 1162.3% | 594.0% | 190.8% | 266.9% | |
| Capex / Sales | 9.8% | 27.0% | 13.9% | 4.6% | 5.1% | |
| SG&A / Sales | 60.4% | 60.2% | 61.3% | 65.0% | 62.5% | |
| R&D / Sales | 10.0% | 10.5% | 10.7% | 12.1% | 10.4% | |
| Stock comp / Sales | 14.0% | 15.4% | 16.4% | 22.6% | 22.0% | |
| Intangibles / Total assets | 1.2% | 1.4% | 1.9% | 2.7% | 0.0% | |
| Days sales outstanding | 112d | 94d | 108d | 103d | 87d | |
| Days payables outstanding | 82d | 134d | 132d | 113d | 66d | |
| Operating cycle | 203d | 192d | 185d | 210d | 185d | |
| Cash conversion cycle | 121d | 58d | 53d | 97d | 119d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-15 Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biotechnology company''s stock after buying an additional 180,761 shares during the period. Bank of America Corp DE owned
- 2026-07-30 Vericel Q2 Earnings Call Highlights Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
- 2026-07-30 Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
- 2026-07-30 Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.
- 2026-07-30 Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.
- 2026-07-21 Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,003 shares of the biotechnology company''s stock after selling 21,710 shares during the quarter. Allspring Global Investments Holdings
- 2026-07-16 Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel''s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
- 2026-06-27 Vericel Stock Is Up 10%. Here''s What This $402,000 Insider Sale Really Suggests 10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin''s direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.
- 2026-06-09 Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026 BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.
- 2026-05-30 Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.